| Identification | Back Directory | [Name]
(ASP371)-TYROSINASE (369-377) (HUMAN) | [CAS]
168650-46-2 | [Synonyms]
CMM8
OCA1A
OCAIA
SHEP3
YMDGTMSQV
[ASP370]-TYROSINASE (368-376)
ASP371, TYROSINASE 369-777, HUMAN
Tyrosinase Fragment 369-377 human
TYR-MET-ASP-GLY-THR-MET-SER-GLN-VAL
(ASP371)-TYROSINASE (369-377) (HUMAN)
H-TYR-MET-ASP-GLY-THR-MET-SER-GLN-VAL-OH
L-Tyrosyl-L-methionyl-L-α-aspartylglycyl-L-threonyl-L-methionyl-L-seryl-L-glutaminyl-L-valine
L-Valine, L-tyrosyl-L-methionyl-L-α-aspartylglycyl-L-threonyl-L-methionyl-L-seryl-L-glutaminyl-
(Asp371)-Tyrosinase (369-377) (human) acetate salt H-Tyr-Met-Asp-Gly-Thr-Met-Ser-Gln-Val-OH acetate salt
(Asp371)-Tyrosinase (369-377) (human) trifluoroacetate salt H-Tyr-Met-Asp-Gly-Thr-Met-Ser-Gln-Val-OH trifluoroacetate salt | [Molecular Formula]
C42H66N10O16S2 | [MDL Number]
MFCD01318791 | [MOL File]
168650-46-2.mol | [Molecular Weight]
1031.16 |
| Chemical Properties | Back Directory | [Boiling point ]
1578.2±65.0 °C(Predicted) | [density ]
1.375±0.06 g/cm3(Predicted) | [storage temp. ]
-15°C
| [solubility ]
deionized water: soluble | [form ]
lyophilized powder | [pka]
3.32±0.10(Predicted) | [color ]
white | [Sequence]
Tyr-Met-Asp-Gly-Thr-Met-Ser-Gln-Val |
| Hazard Information | Back Directory | [Uses]
Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy[1][2]. | [References]
[1] Guillaume B, et al. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J Immunol. 2012 Oct 1;189(7):3538-47. DOI:10.4049/jimmunol.1103213
[2] Mitchell MS, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 2002 Feb 15;20(4):1075-86. DOI:10.1200/JCO.2002.20.4.1075 |
|
|